000 01239 a2200337 4500
005 20250517020750.0
264 0 _c20150518
008 201505s 0 0 fre d
022 _a1769-6917
024 7 _a10.1016/j.bulcan.2015.01.007
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLieutenant, Vincent
245 0 0 _a[Is Herceptin(®) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study].
_h[electronic resource]
260 _bBulletin du cancer
_cMar 2015
300 _a270-6 p.
_bdigital
500 _aPublication Type: English Abstract; Journal Article; Review
650 0 4 _aAdministration, Cutaneous
650 0 4 _aAntibodies, Monoclonal, Humanized
_xadministration & dosage
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aBreast Neoplasms
_xdrug therapy
650 0 4 _aDrug Administration Schedule
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aTime Factors
650 0 4 _aTrastuzumab
700 1 _aToulza, Émilie
700 1 _aPommier, Martine
700 1 _aLortal-Canguilhem, Barbara
773 0 _tBulletin du cancer
_gvol. 102
_gno. 3
_gp. 270-6
856 4 0 _uhttps://doi.org/10.1016/j.bulcan.2015.01.007
_zAvailable from publisher's website
999 _c24664236
_d24664236